Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69746 | 0.88 | FFAR1 (0.81) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL452845 | 0.87 | SMN1; SMN2 (0.67) | FFAR1KEAP1LMNA | |
| Hydrochloric Acid SCHEMBL25264643 | 0.85 | FFAR1 (0.77) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL2197174 | 0.85 | MAPT (0.66) | FFAR1LMNA | |
| SCHEMBL27864939 | 0.84 | F2RL1 (0.47) | FFAR1KEAP1L3MBTL1 | |
| SCHEMBL9860436 | 0.84 | MAPT (0.69) | FFAR1 | |
| SCHEMBL2835656 | 0.84 | MAPT (0.69) | FFAR1 | |
| Iocanlidic Acid SCHEMBL290025 | 0.84 | MAPT (0.69) | FFAR1 | |
| SCHEMBL25575670 | 0.84 | MAPT (0.69) | FFAR1 | |
| SCHEMBL6926013 | 0.82 | FFAR1 (0.65) | FFAR1KEAP1FFAR4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137643-A | Composite material, preparation method thereof, photoelectric device and display device | 广东聚华新型显示研究院 | 2025-06-13 | — | — | CN | claimed |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2024-02-15 | — | — | US | claimed |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | claimed |
| US-20230165979-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOSITIONS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2023-06-01 | — | — | US | claimed |
| CN-115989042-A | Copper-containing theranostic compounds and methods of use | 康奈尔大学 | 2023-04-18 | — | — | CN | claimed |
| EP-4146236-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOUNDS AND METHODS OF USE | Cornell University (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2021225760-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOUNDS AND METHODS OF USE | CORNELL UNIVERSITY (US) | 2021-11-11 | — | — | WO | claimed |
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2021-04-29 | — | — | US | claimed |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY (US) | 2020-12-31 | — | — | US | claimed |
| US-10806806-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | CORNELL UNIVERSITY (US) | 2020-10-20 | — | — | US | claimed |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | CORNELL UNIVERSITY | 2019-01-17 | — | — | US | claimed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | claimed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0438233-A2 | Orally active renin inhibitors | PFIZER INC. (US) | 1991-07-24 | — | — | EP | disclosed |
| US-4252719-A | REMOVAL OF A TERTIARY HYDROGEN FROM A 5-A-STEROID BY CHLORINATING THE STEROID BEING FIRST ESTERIFIED BY AN IODOARYL-CONTAINING ESTERIFICATION AGENT | RESEARCH CORPORATION (US) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121584-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
| US-20260091008-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, CD47, KLK3 | FFAR1 1436/4885KEAP1 4104/4885FFAR4 2935/4885 |
| US-20230285603-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
| US-20240050599-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
| US-20200405888-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
| US-10806806-B2 | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
| US-20230165979-A1 | COPPER-CONTAINING THERAGNOSTIC COMPOSITIONS AND METHODS OF USE | SHBG, FABP6, SERPINA6 | FFAR1 2787/4885KEAP1 449/4885FFAR4 3399/4885 |
| US-20190015531-A1 | TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES | VHL, GLS, GPER1 | FFAR1 1717/4885KEAP1 1205/4885FFAR4 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.